The American Journal of Medicine
Volume 121, Issue 1 , Pages 58-65 , January 2008

CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities

  • Herman Schargrodsky, MD

      Affiliations

    • Department of Cardiology, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
    • Corresponding Author InformationRequests for reprints should be addressed to Herman Schargrodsky, MD, Ramón Falcón 2239, 4o. piso, Ciudad Autónoma de Buenos Aires, Argentina, 1406.
    • ,
  • Rafael Hernández-Hernández, MD

      Affiliations

    • Clinical Pharmacology Unit and Hypertension Clinic, School of Medicine, Universidad Centroccidental “Lisandro Alvarado,” Decanato de Medicina, Barquisimeto, Venezuela
    • ,
  • Beatriz Marcet Champagne, PhD

      Affiliations

    • InterAmerican Heart Foundation, Dallas, Tex
    • ,
  • Honorio Silva, MD

      Affiliations

    • Science and Medical Professional Development, Pfizer, Inc., New York, NY
    • ,
  • Raúl Vinueza, MD

      Affiliations

    • Latin America Biometrics Center, Pfizer, Inc., New York, NY
    • ,
  • Luis Carlos Silva Ayçaguer, PhD

      Affiliations

    • Centro Nacional de Información de Ciencias Médicas, La Habana, Cuba
    • ,
  • Pierre-Jean Touboul, MD

      Affiliations

    • Bichet Hospital and University, Paris, France
    • ,
  • Carlos Pablo Boissonnet, MD

      Affiliations

    • Coronary Care Unit, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno,” Ciudad Autónoma de Buenos Aires, Argentina
    • ,
  • Jorge Escobedo, MD

      Affiliations

    • Medical Research Unit on Clinical Epidemiology, Mexican Social Security Institute, Mexico City, Mexico
    • ,
  • Fabio Pellegrini, MSc

      Affiliations

    • Consorzio Mario Negri Sud, Chieti, Italy
    • ,
  • Alejandro Macchia, MD

      Affiliations

    • Consorzio Mario Negri Sud, Chieti, Italy
    • ,
  • Elinor Wilson, PhD

      Affiliations

    • Assisted Human Reproduction Canada, Ottawa, Ontario, Canada.
    • ,
  • CARMELA Study Investigators

References 

  1. Omran A. The epidemiologic transition: a theory of the epidemiology of population change. Millbank Memorial Fund Q. 1971;49:509–538
  2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–2753
  3. World Health Organization. The World Health Report: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization; 2002;
  4. Ordunez P, Silva LC, Rodriguez MP, Robles S. Prevalence estimates for hypertension in Latin America and the Caribbean: are they useful for surveillance?. Rev Panam Salud Publica. 2001;10:226–231
  5. World Health Organization. Preventing Chronic Diseases: A Vital Investment. Geneva: World Health Organization; 2005;
  6. Torres MI, Quiroga SE, Farinati ZJ. Pilot external quality assessment scheme for serology determinations in Latin America. Clin Chem Lab Med. 1999;37:S299;Special Supplement
  7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  8. National Cholesterol Education Program Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  9. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S5–S20
  10. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004;18:346–349
  11. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–223
  12. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199–206
  13. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation. 2003;107:2185–2189
  14. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Geneva: World Health Organization; 2000;
  15. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition (A Consensus Statement from the International Diabetes Federation). Diabet Med. 2006;23:469–480
  17. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  18. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–1529
  19. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769–1778
  20. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97:596–601
  21. Ezzati M, Vander Hoorn S, Lawes CM, et al. Rethinking the “diseases of affluence” paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med. 2005;2:e133
  22. United Nations Development Programme. Human Development Report 2005 International Cooperation at a Crossroads: Aid, Trade and Security in an Unequal World. New York: United Nations; 2005;
  23. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tob Control. 1994;3:242–247
  24. World Conference on Tobacco or Health. Tobacco Control Country Profiles. American Cancer Society, World Health Organization, and International Union Against Cancer; 2003;
  25. Bots ML. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin. 2006;22:2181–2190
  26. Touboul PJ, Vicaut E, Labreuche J, et al. Design, baseline characteristics and carotid intima-media thickness reproducibility in the PARC study. Cerebrovasc Dis. 2005;19:57–63
  27. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76:4–12
  28. Stamler J. Established major coronary risk factors. In:  Marmot M,  Elliott P editor. Coronary Heart Disease: From Aetiology to Public Health. Oxford University Press; 1992;
  29. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327:1267
  30. Lanas F, Avezum A, Bautista LE, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation. 2007;115:1067–1074

 The CARMELA Study was funded through an unrestricted research grant from Pfizer, Inc.

PII: S0002-9343(07)00940-0

doi: 10.1016/j.amjmed.2007.08.038

The American Journal of Medicine
Volume 121, Issue 1 , Pages 58-65 , January 2008

Article Tools